We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders
Read MoreHide Full Article
Biogen, Inc. (BIIB - Free Report) announced a collaboration deal with New Jersey based gene therapy company, Capsigen to discover and develop novel AAV capsids for targeted central nervous system (CNS) and neuromuscular disorders. These AAV capsids, to be discovered by utilizing Capsigen’s proprietary TRADE platform, have the potential to be developed into transformative gene therapies that can address the underlying genetic causes of such disorders.
These AAV capsids with improved delivery profiles hold the potential to solve key technological problems faced in the delivery of gene therapies to target tissue. Per the deal, Biogen gets rights to Capsigen’s proprietary technology for an undisclosed number of CNS and neuromuscular disease targets against an upfront payment of $15 million. In addition, Capsigen will be eligible to receive up to $42 million in potential research milestones and up to an additional $1.25 billion in potential development and commercial fees should the deal achieve certain development/sales milestones.
Biogen’s stock has risen 13.6% this year so far against a decrease of 5.2% for the industry
Biogen is trying to diversify its pipeline and aims to be a leader in neuroscience and the adjacent therapeutic area. In almost four years from 2017-2020, Biogen executed 20 business development transactions, which significantly boosted its pipeline.
Among some recent deals, Biogen signed a collaboration with Sangamo Therapeutics (SGMO - Free Report) in 2020 to make gene regulation therapies for a range of neurological indications including Alzheimer's disease. It also collaborated with Denali Therapeutics (DNLI - Free Report) in August 2020 to co-develop and co-commercialize the latter’s small molecule LRRK2 inhibitor program, DNL151, for Parkinson’s disease, which will enter late-stage development in 2021.In November 2020, Biogen signed a collaboration with Sage Therapeutics (SAGE - Free Report) , which added a late-stage program (zuranolone) in depression and movement disorders.
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Image: Bigstock
Biogen (BIIB) Signs New Gene Therapy Deal for CNS Disorders
Biogen, Inc. (BIIB - Free Report) announced a collaboration deal with New Jersey based gene therapy company, Capsigen to discover and develop novel AAV capsids for targeted central nervous system (CNS) and neuromuscular disorders. These AAV capsids, to be discovered by utilizing Capsigen’s proprietary TRADE platform, have the potential to be developed into transformative gene therapies that can address the underlying genetic causes of such disorders.
These AAV capsids with improved delivery profiles hold the potential to solve key technological problems faced in the delivery of gene therapies to target tissue. Per the deal, Biogen gets rights to Capsigen’s proprietary technology for an undisclosed number of CNS and neuromuscular disease targets against an upfront payment of $15 million. In addition, Capsigen will be eligible to receive up to $42 million in potential research milestones and up to an additional $1.25 billion in potential development and commercial fees should the deal achieve certain development/sales milestones.
Biogen’s stock has risen 13.6% this year so far against a decrease of 5.2% for the industry
Biogen is trying to diversify its pipeline and aims to be a leader in neuroscience and the adjacent therapeutic area. In almost four years from 2017-2020, Biogen executed 20 business development transactions, which significantly boosted its pipeline.
Among some recent deals, Biogen signed a collaboration with Sangamo Therapeutics (SGMO - Free Report) in 2020 to make gene regulation therapies for a range of neurological indications including Alzheimer's disease. It also collaborated with Denali Therapeutics (DNLI - Free Report) in August 2020 to co-develop and co-commercialize the latter’s small molecule LRRK2 inhibitor program, DNL151, for Parkinson’s disease, which will enter late-stage development in 2021.In November 2020, Biogen signed a collaboration with Sage Therapeutics (SAGE - Free Report) , which added a late-stage program (zuranolone) in depression and movement disorders.
Biogen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020 Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2021 today >>